MedMesh.i
Corpus
PubMed
Racine
Corpus
Checkpoint
PubMed
Racine
PubMed
Exploration
Accueil
Racine
Racine

La maladie de Parkinson en France (serveur d'exploration) - Corpus (PubMed)

Index « MedMesh.i » - entrée « Selegiline »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Selection, Genetic < Selegiline < Selenoproteins  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 11.
Ident.Authors (with country if any)Title
001118 (2003) Olivier RascolMonoamine oxidase inhibitors--is it time to up the TEMPO?
001175 (2002) Selegiline: a second look. Six years later: too risky in Parkinson's disease.
001245 (2001) N. Callizot ; J L Guénet ; C. Baillet ; J M Warter ; P. PoindronThe frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
001534 (1997) N. Andreu ; C. Damase-Michel ; J M Senard ; O. Rascol ; J L MontastrucA dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
001566 (1996) J L Montastruc ; O. Rascol ; J M SenardNew directions in the drug treatment of Parkinson's disease.
001647 (1995) H. Lefebvre ; C. Noblet ; N. Moore ; L M WolfPseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.
001716 (????) [Monotherapy trial with selegiline in de novo parkinsonian patients] Members of the French research group for testing selegiline in early Parkinson disease].
001745 (1993) H. Allain ; P. Pollak ; H C NeukirchSymptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.
001791 (????) J L MontastrucRecent advances in the clinical pharmacology of Parkinson's disease.
001800 (1991) H. Allain ; J. Cougnard ; H C NeukirchSelegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT).
001862 (1988) O. Rascol ; J L Montastruc ; J M Senard ; J F Demonet ; M. Simonetta ; A. RascolTwo weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/MedMesh.i -k "Selegiline" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/MedMesh.i  \
                -Sk "Selegiline" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Selegiline
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024